Stephen Andrew Cohen sold $22M of PLTR
See Remarks at Palantir Technologies Inc.. 348,809 shares at an average of $61.80, traded Nov 20, 2024, filed Nov 22, 2024.
Score components
- +15RoleOfficer
- +25Trade size$21.6M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001321655-24-000225, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | CConversion Class A Common Stock10b5-1 | +229,754 | - | - | 230,346 | Nov 22, 2024 |
| Nov 20, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -45,261 | $60.68 | $2.7M | 185,085 | Nov 22, 2024 |
| Nov 20, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -114,494 | $61.61 | $7.1M | 70,591 | Nov 22, 2024 |
| Nov 20, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -69,999 | $62.21 | $4.4M | 592 | Nov 22, 2024 |
| Nov 21, 2024 | CConversion Class A Common Stock10b5-1 | +119,055 | - | - | 119,647 | Nov 22, 2024 |
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -48,563 | $61.29 | $3.0M | 71,084 | Nov 22, 2024 |
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -69,580 | $62.76 | $4.4M | 1,504 | Nov 22, 2024 |
| Nov 21, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -912 | $63.07 | $58k | 592 | Nov 22, 2024 |
| Nov 20, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -675,000 | $0.00 | $0 | 4,050,000 | Nov 22, 2024 |
| Nov 20, 2024 | MOption exercise Class B Common Stockderivative10b5-1 | +675,000 | $0.00 | $0 | 13,867,596 | Nov 22, 2024 |
| Nov 20, 2024 | CConversion Class B Common Stockderivative10b5-1 | -229,754 | $0.00 | $0 | 13,637,842 | Nov 22, 2024 |
| Nov 21, 2024 | CConversion Class B Common Stockderivative10b5-1 | -119,055 | $0.00 | $0 | 13,518,787 | Nov 22, 2024 |
Related signals
Other insiders at Palantir Technologies Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | Palantir Technologies Inc. | Lauren Elaina Friedman Stat director | $254k 1,337 shares | -3% | |
| 28Weak | Palantir Technologies Inc. | Alexander D. Moore director | $2.8M 16,000 shares | -1% | |
| 16Weak | Palantir Technologies Inc. | Lauren Elaina Friedman Stat director | $245k 1,342 shares | -2% | |
| 33Weak | Palantir Technologies Inc. | Lauren Elaina Friedman Stat director | $1.6M 9,000 shares | -15% | |
| 45Moderate | Palantir Technologies Inc. | Lauren Elaina Friedman Stat director | $3.5M 21,000 shares | -26% | |
| 40Moderate | Palantir Technologies Inc. | Ryan D. Taylor See Remarks | $5.7M 36,048 shares | -10% | |
| 25Weak | Palantir Technologies Inc. | David A. Glazer See Remarks | $13M 81,000 shares | -16% | |
| 35Weak | Palantir Technologies Inc. | Alexander D. Moore director | $3.1M 20,000 shares | -2% | |
| 27Weak | Palantir Technologies Inc. | Jeffrey Buckley See Remarks | $440k 2,803 shares | -5% | |
| 25Weak | Palantir Technologies Inc. | Jeffrey Buckley See Remarks | $363k 2,365 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.